Venous thromboembolism (VTE), is major source of morbidity and mortality in cancer patients. 

Incidence rates of cancer-associated thrombosis (CAT) vary with cancer type, stage, treatment, and comorbidities, but it is estimated that approximately 15-20 % of cancer patients will develop a venous thromboembolic episode at some point during the course of their illness.